Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Visual outcomes and complications rate of Boston type I keratoprosthesis: single-center study

Poster Details

First Author: A.Alosaily SAUDI ARABIA

Co Author(s):    S. Almotowa   H. Osorio   J. Vargas              

Abstract Details

Purpose:

To evaluate the outcomes and complications rate of the Boston type I Keratoprosthesis (KPro-1) at our institute

Setting:

King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

Methods:

A retrospective chart review was performed on all cases of KPro-1 implantation from January 1, 2010, through December 31, 2014 with minimum of six months follow up. Eyes in which the KPro-1 procedure was the primary corneal procedure or was the first keratoprosthesis procedure for an eye with one or more previous keratoplasties were included in the statistical analysis. Experienced member of the corneal surgeons performed the KPro-1 procedures.

Results:

There were 32 patients, 81.25% were male. Mean age was 64.28 years and mean follow-up was 43.5 months. The primary indication was multiple failed grafts in 65.6%. Postoperative complications included retroprosthetic membrane (53.13%), increased intraocular pressure or escalating pre-existing glaucoma (43.75%), microbial keratitis (18.75%), sterile keratolysis (12.5%), and retinal detachment and endophthalmitis (each 9.38%). Twenty-nine KPros (90.6%) were retained at the last follow up. Mean best-corrected visual acuities were 2/200 preoperatively (range: light perception to 20/300), 20/125 at any point postoperative (range: light perception to 20/25), and 20/200 at the last follow up (range: no light perception to 20/25).

Conclusions:

Retention rates were excellent, and best-corrected visual acuities improved in the vast majority of patients. Complications can occur and require frequent follow-up to monitor and treat glaucoma progression, endophthalmitis, and inflammation. Despite the potential complications, the Boston KPro provides visual improvement in patients with an otherwise poor prognosis.

Financial Disclosure:

None

Back to Poster listing